Novel Coronavirus Information Center
Elsevier’s free health and medical research on the novel coronavirus (SARS-CoV-2) and COVID-19
Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on SARS-CoV-2 and COVID-19.
All resources are free to access.
Under the Research tab, you can access early-stage and peer-reviewed research on COVID-19 from our journals, including The Lancet and Cell Press. We have made more than 63,000 COVID-related Elsevier journal articles and book chapters free to access on ScienceDirect and PubMedCentral.
These articles are also available to download over FTP with rights for full text and data mining, re-use and analyses for as long as needed.
- Server address: coronacontent.np.elsst.com
- Protocol: sftp (SSH File Transfer Protocol)
- Username: public
- Password: beat_corona
We share daily updates to this corpus with the Allen Institute for inclusion in the multi-publisher CORD-19 dataset.
Under the Clinical information tab, you will find evidence-based skill guides and care plans for treatment, safety and patient education, along with emergency prepared resources.
In the Patient resources section, you can find our 3D4Medical coronavirus video, resources from the CDC and WHO, and information about Elsevier's Patient Access Program for research.
Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier
As the highly contagious Delta variant rages on and more children are being affected, prevention continues to be of utmost importance, with a focus is on vaccines and their long-term effectiveness as well as masking. Our Clinical Information section has guidance for clinicians; and our Research, Vaccines & drug discovery, and Public health sections have information and resources for researchers and public health experts.
When we created this resource in January 2020, we anticipated “an explosion of clinical and epidemiological information and research,” and we have certainly seen that. Our goal was to open whatever resources we could to help public health authorities, researchers and clinicians contain and manage this disease. We continue to provide regularly updated resources from Elsevier's content and experts. Our resources span scientific and medical journals, educational products — including our clinically focused COVID-19 Healthcare Hub — and periodic podcast interviews with internationally-recognized experts.
We are also participating in the Education Continuity License from the Copyright Clearance Center, allowing the use of publishers’ materials in distance-learning models and other uses as required by the pandemic at no cost to the user.
In addition, Elsevier has from the beginning enabled full text and data mining of this growing body of knowledge through channels such as the NIH’s PubMed Central and the WHO database for free and without copyright limitations.
Elsevier, Cell Press and The Lancet have also joined the signatories on the Wellcome Trust’s Statement, designed to ensure that research findings and data relevant to this outbreak are shared rapidly and openly to inform the public health response and help save lives.
Elsevier has been pleased and proud to provide these resources to more than 2 million users, and we are committed to doing so as the pandemic grinds on.
If you're looking for information on our other free and low-cost access programs, including resources for patients and caregivers, you can find that here.
In this section, you can find resources from Elsevier Clinical Solutions, including guidance from ClinicalKey, Clinical Skills for Nursing, Interprofessional care plans and Patient Education resources. For more clinical information, please visit:
Gain access to our latest evidence-based practices and resources for COVID-19, covering topics from symptom management to diagnosis, treatment and ongoing wellness.
These resources include Clinical Overviews on ClinicalKey — easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops them through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.
Elsevier has created a dedicated COVID-19 Healthcare Hub for clinicians in India.
In Elsevier's podcast series for frontline clinicians and providers, experts share their insights into the mode of transmission and pathophysiology of the virus, how medical informatics and telemedicine are used to manage the pandemic, and best practices for emergency nursing crisis preparedness.
Mental and behavioral health
With the fear and uncertainty brought on by the pandemic — and calls for social distancing — many people are experiencing increased stress, anxiety and depression. Our evidence-based patient education resources support professional practice guidelines, presenting information in a way that is easy to understand and actionable. You can find more resources in Elsevier's Mental and Behaviorial Healthcare Hub.
Elsevier has created this anxiety screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 13 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.
Book chapters and peer-reviewed articles from Elsevier journals
- Anxiety Disorders, Chapter 24, Stress: Concepts, Cognition, Emotion, and Behavior: Handbook in Stress Series, Volume 1 (Academic Press, 2016)
- Fatigue and Stress, Chapter 42, Concepts, Cognition, Emotion, and Behavior (Academic Press, 2016)
- Exercise for the Management of Anxiety and Stress-Related Disorders, Chapter 2, Exercise-Based Interventions for Mental Illness (Academic Press, 2018)
- Anxiety (Generalized Anxiety Disorder), Ferri's Clinical Advisor (Elsevier, 2020)
- Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: a web-based cross-sectional, Psychiatry Research (June 2020)
- Epidemic of COVID-19 in China and associated Psychological Problems, Asian Journal of Psychiatry (June 2020)
Elsevier has created this depression screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 18 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.
Book chapters and peer-reviewed articles from Elsevier journals
- Novac, Andrei, MD: Depressive, Bipolar, and Related Mood Disorders, Conn's Current Therapy (Elsevier, 2020 )
- Zimmerman M, D’Avanzato C: Major Depression, Ferri's Clinical Advisor (Elsevier, 2020)
- The role of social integration in the adverse effect of unemployment on mental health – Testing the causal pathway and buffering hypotheses using panel data, Social Science Research (Feb 2020)
- The psychological impact of quarantine and how to reduce it: rapid review of the evidence, The Lancet (March 2020)
- Suicidal thoughts and behaviors and social isolation: A narrative review of the literature, Journal of Affective Disorders (Feb 2019)
Related stories by Elsevier book authors
Resources from Elsevier's Clinical Solutions team in China
|Date||Title||Published by (CN)||Published by (EN)||Link|
National Microbiological Data Center;|
National Pathogen Resource Collection Center
View more resources
|Diagnosis & Treatment Guidelines 诊疗指南|
|4月16日||新冠肺炎疫情社区防控与服务工作精准化精细化指导方案||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202004/7838c406600d4d38a11f5675c98a2ecf.shtml|
|4月14日||大专院校新冠肺炎疫情防控技术方案||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202004/7838c406600d4d38a11f5675c98a2ecf.shtml|
|4月13日||Guidelines for Investigation and Management of Close Contacts of COVID-19 Cases||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/aa16e57b-d717-40f0-bf34-265c6e011508|
|4月13日||Technical Guidelines for COVID-19 Laboratory Testing||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/0f6dc581-08f4-4828-97f0-9cc805969bbb|
|Chinese Center for Disease Control and Prevention||Guidelines for Personal Protection of Specific Groups from COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/65577621-f02e-4c47-b883-f70659c300b3|
|4月13日||Technical Guidelines for Disinfection of Special Sites for COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/7120f4f9-e03d-4164-9bf2-3e097d4b3734|
|4月11日||Protocol for the Management of Asymptomatic Persons Infected with COVID-19 Virus||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/18987f85-feb8-44c8-b94e-8bdcd8ad141a|
|4月8日||新冠病毒无症状感染者管理规范||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202004/9d3edaaebb9a4c369f42c61039be35fe.shtml|
|4月8日||新冠肺炎出院患者复诊复检工作方案（试行）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202004/1ba91504225040a7ac2c9eda48cc4e7e.shtml|
|4月1日||新型冠状病毒肺炎重型、危重型病例诊疗方案（试行 第二版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202004/c083f2b0e7eb4036a59be419374ea89a.shtml|
|3月29日||Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7)||国家卫生健康委员会||National Health Commission||https://en.nhc.gov.cn/2020-03/29/c_78469.htm|
|3月19日||Guidelines for COVID-19 Epidemiological Investigations||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/99b0a945-a516-410a-9260-7db46e792877|
|3月15日||Guidelines for Investigation and Management of Close Contacts of COVID-19 Cases||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/aa16e57b-d717-40f0-bf34-265c6e011508|
|3月13日||Technical Guidelines for COVID-19 Laboratory Testing||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/0f6dc581-08f4-4828-97f0-9cc805969bbb|
|3月13日||Guidelines for Personal Protection of Specific Groups from COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/65577621-f02e-4c47-b883-f70659c300b3|
|3月13日||Technical Guidelines for Disinfection of Special Sites for COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/7120f4f9-e03d-4164-9bf2-3e097d4b3734|
|3月13日||新冠肺炎出院患者健康管理方案（试行）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202003/056b2ce9e13142e6a70ec08ef970f1e8.shtml|
|3月12日||重症新型冠状病毒肺炎管理专家推荐意见||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/3/12/art_2928_33535.html|
|3月12日||北京协和医院麻醉科手术室新冠肺炎（COVID-19）疫情期间区域分级防护规范（试行）||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/3/12/art_2928_33535.html|
|3月11日||Protocol for Prevention and Control of COVID-19 (Edition 6)||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/e97a6f76-c07f-4d43-bd73-51067a4fc9f9|
|3月7日||新型冠状病毒肺炎防控方案（第六版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202003/4856d5b0458141fa9f376853224d41d7.shtml|
|3月4日||新型冠状病毒肺炎诊疗方案（试行第七版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml|
|2月26日||新型冠状病毒肺炎（NCP）床旁超声心动图检查及远程超声诊断实施方案（第一版）||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/2/26/art_2928_33048.html|
|2月24日||新型冠状病毒肺炎重型、危重型病例诊疗方案（试行第二版）||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/2/24/art_2928_32959.html|
|2月21日||新型冠状病毒肺炎防控方案（第五版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202002/a5d6f7b8c48c451c87dba14889b30147.shtml|
|2月19日||新型冠状病毒肺炎诊疗方案（试行第六版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.shtml|
|2月17日||新型冠状病毒肺炎疫情防控期间养老机构老年人就医指南||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202002/c26a0ca4a58d47489c5781493b2ac624.shtml|
|2月14日||新型冠状病毒感染相关ICD代码||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202002/dcf3333b740f4fabad5f9f908d1fc5b4.shtml|
|2月8日||新型冠状病毒肺炎诊疗方案（试行第五版 修正版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml|
|2月7日||新型冠状病毒感染的肺炎防控方案（第四版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202002/573340613ab243b3a7f61df260551dd4.shtml|
|2月5日||新型冠状病毒感染的肺炎诊疗方案（试行第五版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml|
|2月1日||新型冠状病毒感染的肺炎患者遗体处置工作指引（试行）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/yzygj/s7659/202002/163c26a24057489dbf64dba359c59a5f.shtml|
|1月28日||新型冠状病毒感染的肺炎防控方案（第三版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202001/470b128513fe46f086d79667db9f76a5.shtml|
|1月28日||新型冠状病毒感染的肺炎病例转运工作方案（试行）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202001/ccee6ec0942a42a18df8e5ce6329b6f5.shtml|
|1月27日||新型冠状病毒感染的肺炎诊疗方案（试行第四版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67.shtml|
|1月25日||关于“新型冠状病毒感染的肺炎”诊疗建议方案（V2.0）||中国医学科学院北京协和医院||Peking Union Medical College Hospital, CAMS||https://new.qq.com/omn/HLH20200/HLH2020012501009300.html|
|1月24日||《新型冠状病毒肺炎诊疗快速指南》||华中科技大学同济医学院附属同济医院专家组||Tongji Hospital, Tongji Medical College of HUST||https://xw.qq.com/health/20200124010910/HLH2020012401091000|
|1月24日||《武汉协和医院处置2019新型冠状病毒感染策略及说明》||华中科技大学同济医学院附属协和医院专家组||Xiehe Hospital, Tongji Medical College of HUST||https://www.dxy.cn/bbs/newweb/pc/post/42662254|
|1月23日||湖北省新型冠状病毒感染的肺炎诊疗方案(试行第一版）||湖北省医疗救治专家组||Medical Expert Panel of Hubei Province||https://xw.qq.com/cmsid/20200123A0KNOW00|
|1月23日||医疗机构内新型冠状病毒感染预防与控制技术指南（第一版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml|
|1月23日||新型冠状病毒实验室生物安全指南（第二版）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml|
|1月22日||新型冠状病毒感染的肺炎诊疗方案（试行第三版）（PDF可下载）||国家卫生健康委员会||National Health Commission||https://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml|
|Epidemic situation 疫情分布|
|Daily update||新型冠状病毒感染的肺炎疫情分布||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://2019ncov.chinacdc.cn/2019-nCoV/|
|Research articles 研究进展和经典图书|
|4月30日||Nursing Management in General Hospitals during the Prevention and Control of COVID-19||北京大学医学出版社||Peking University Medical Press||https://cdn.pumpedu.com.cn/pdfview/index.php?cc=21650en|
|4月30日||Handbook of Common Nursing Technology for COVID-19||北京大学医学出版社||Peking University Medical Press||https://cdn.pumpedu.com.cn/pdfview/index.php?cc=21667en|
|4月30日||Specialty Issues in the Management and Treatment of COVID-19||北京大学医学出版社||Peking University Medical Press||https://cdn.pumpedu.com.cn/pdfview/index.php?cc=21634en|
|4月19日||Handbook of Basic Epidemiological Knowledge on Coronavirus Disease 2019(COVID-19)-110 Questions & Answers||北京大学医学出版社||Peking University Medical Press||https://mp.weixin.qq.com/s/FCegqoxc5X72uqdsulzc1A|
|4月19日||《新型冠状病毒肺炎流行病学知识110问》||北京大学医学出版社||Peking University Medical Press||https://mp.weixin.qq.com/s/zkPzfFLuPDdymj0od4eUHw|
|4月2日||COVID-19 Academic Research Communication Platform (English) - Free to read||中华医学会杂志社||CMA Publishing House||https://medjournals.cn/COVID-19/index.do|
|4月2日||新型冠状病毒肺炎科研成果学术交流平台（中文）- 免费阅读||中华医学会杂志社||CMA Publishing House||https://medjournals.cn/2019NCP/index.do|
|2月28日||COVID-19影像表现及研究进展||中华医学会放射学分会青年委员会||Youth Committee, Radiology Branch of Chinese Medical Association||https://mp.weixin.qq.com/s/MnJyIzobbDQdicAQScG1ow|
|2月18日||A strategy to prevent future epidemics similar to the 2019-nCoV outbreak||Biosafety and Health||Biosafety and Health||https://www.sciencedirect.com/science/article/pii/S2590053620300161|
|2月18日||Technical guidance for laboratory testing of 2019-nCoV infection (third edition)||Biosafety and Health||Biosafety and Health||https://www.sciencedirect.com/science/article/pii/S2590053620300136|
|2月18日||Laboratory biosafety guide for the novel coronavirus||Biosafety and Health||Biosafety and Health|
|1月25日||中国新型冠状病毒感染病例首批临床数据报告（解读, with link to sourse articles）||The Lancet Weichat Official Account||The Lancet Weichat Official Account|
|1月22日||Notes from the Field: An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province...[2020-01-22]||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/e3c63ca9-dedb-4fb6-9c1c-d057adb77b57|
|1月21日||A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019-2020[2020-01-21]||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||https://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c|
|1月21日||引自《默里及纳达尔呼吸医学》，V Courtney Broaddus 主编，李为民、程德云主译，人民卫生出版社，2018||李为民、程德云主译，人民卫生出版社，2018||Elsevier, with content quoted from translation published by PMPH||Influenza|
|Patient Education 患者教育|
|2020.1.24||轻症疑似2019新型冠状病毒患者及密切接触人员如何进行自我管理||北京协和医院呼吸科||Respiratory Department, Peking Union Medical College Hospital, CAMS||https://m.sohu.com/a/368777653_102327|
In this section, you can find the following resources:
- Journal articles, including coronavirus hubs by The Lancet and Cell Press
- Early-stage research (preprints on SSRN)
- Infographic: global research trends in infectious disease
- Interactive map: global disease outbreak experts
Related articles freely available on ScienceDirect
Elsevier has made coronavirus-related articles and book chapters freely available for as long as is necessary, commencing in February 2020. This content is freely available on ScienceDirect and PubMedCentral
Additional resources include:
On this Coronavirus Resource Hub, curated by members of the Cell Press editorial team, you'll find content about the outbreak as it appears in Cell Press journals along with our policies for submitting papers.
1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It includes quality controlled academic and research documents in all disciplines and languages, from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals. The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.
This French version of our Novel Coronavirus Information Center includes regular updates on research in French journals.
Content hubs from other publishers
Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | American College of Cardiology| Chongqing VIP Information. Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.
You can find all these publishers and more on LitCovid — the National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.
Early-stage research: preprints on SSRN
Rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.” SSRN , Elsevier’s platform for the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.
Top 10 SSRN downloads of the week*
- Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France 266
- International Law of State Responsibility and COVID-19: an Ideology Critique 122
- SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results 114
- The Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV, Multicentre Randomised Controlled Trial with Blinding (ComFluCOV) 47
- Redesigning Widespread Insurance Coverage Disputes: A Case Study of the British and American Approaches to Pandemic Business Interruption Coverage 31
- Last in Line: Vaccine Scarcity and the Americans with Disabilities Act 29
- Voting Amid COVID: The Response of Voters to Voting during the Pandemic 27
- State or Civil Society – What Matters in Fighting COVID-19? A Comparative Analysis of Hong Kong and Singapore 19
- The Lived Experience of Health Insurance 18
- Risks of Emergency Department Visits, Hospitalisations, Life-Threatening Events, and Deaths After SARS/nCoV2 Vaccination in the US: An Observational Study Using National Data 15
* Calculated on Friday, Oct 1, 2021
Infographic: Global research trends
Download Elsevier’s infographic on infectious disease research trends, top research orgs and the impact of outbreaks
Interactive map: global coronavirus experts
This map represents the most active institutions researching COVID-19 and related coronaviruses. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications related to COVID-19, coronaviruses and related diseases such as SARS and MERS. We then used the resulting ~96,000 publications to identify the currently active researchers and institutions that are working in these areas, the map shows the most prolific global institutions and links to their authors. (Updated: September 8, 2021)
Click on a pin to see more about the institution, the numbers of researchers and their publications that matched our query in Scopus. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.
The 15th Vaccine Congress will take place online as a live-streamed and interactive event on October 4-6, 2021. The Congress is organized by Vaccine, the premier journal for those interested in vaccine science. Leading experts from around the world will join us online to share their knowledge on the current groundbreaking developments and discoveries in the field, including the frontrunner COVID vaccines.You will also have the opportunity to share and present your research and form new relationships with potential collaborators.
BioNTech co-founder talks about developing the Covid vaccine with Pfizer — and experts answer questions from a global audience
COVID-19 drug therapy
You can find up-to-date information in Elsevier's Community Pharmacy Toolkit including:
Drug information from Elsevier's R&D Solutions
Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we use those tools to generate information relevant to combating COVID-19:
- Pathways depicting SARS molecular biology. These pathways were created to find protein targets for drug re-purposing against COVID-19. They were built by manually curating data extracted by Elsevier NLP from COVID-19 scientific articles and from their supplemental materials using Pathway Studio, which helps researchers analyze experimental data to understand the biological processes critical to their work.
- 121 drugs and natural products successfully used against previous coronavirus infections including SARS. This list was generated using Elsevier's Pathway Studio.
- 393 substances that interact with 25 targets related to 6 target species including SARS coronavirus, Middle East respiratory syndrome coronavirus, human Middle East respiratory syndrome coronavirus, Human coronavirus 229E, Coronaviridae and Coronavirinae, with normalized affinity value > 6. This list was generated using Elsevier’s Reaxys Medicinal Chemistry.
- Autophagy is a cellular recycling process, whereby cells eliminate damaged or diseased components in order to regenerate and build new healthier cells; thus, viruses are usually identified and disposed of in this way. Would it be possible to induce the autophagy process and limit the viral infection by using some substances? Pathway Studio provides a list of 406 compounds that have been reported inhibiting autophagy pathway, and their related references as well as a list of 802 compounds that have activating roles in autophagy.
Pure portal: Discover research collaborators and institutions globally
Use this Pure portal to discover novel coronavirus related research collaborators and institutions around the world. It uses Elsevier’s Natural Language Fingerprinting technology, scientific taxonomies and Scopus profiles and can be used to filter and find associated publications.
Gender and COVID-19 Group on Mendeley
This collection of research, studies and other references covers the sex and gender dimensions of the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. The library is a public group, free for anyone in the world to join, access and add. References – articles, preprints, news articles, blog posts, magazine articles, reports, etc – include those compiled by Dr. Rosemary Morgan at Johns Hopkins University and colleagues from the Gender and COVID-19 Working Group, as well as those from other compilations and sources. The library on the Mendeley platform includes >500 references related to Gender and COVID-19, as well as gender and other infectious disease/epidemics, which you can locate and find resources, include direct citations and references within your work, and add additional references & folders directly to the group. We invite the community to continue posting new references as they’re published/become available even if also being added to an existing compilation elsewhere.
Here, you will find guidance and commentary from experts along with official guidance from major health organizations such as the CDC and WHO. For research on public health and related topics, see our Research section.
By combining their data and analytics with those of other industry stakeholders, LexisNexis Health Care created a COVID-19 dataset and interactive visualization to provide insights on at-risk populations and care capacity risks. View the map
This special issue in the Journal of Aerosol Science, from 2018, has articles that are relevant to COVID-19.
COVID-19 Pandemic Collection in AJPM
View this collection in the American Journal of Preventive Medicine
Articles in this COVID-19 Pandemic collection cover pressing public health issues, including vulnerable populations at risk and economic impact:
View the articles
- Relationships Between Initial COVID-19 Risk Perceptions and Protective Health Behaviors: A National Survey
- Preventing COVID-19 and its Sequela: “There Is No Magic Bullet ... It's Just Behaviors”
- Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China
- COVID-19 and the Correctional Environment: The American Prison as a Focal Point for Public Health
- Vulnerable Populations: Weathering the Pandemic Storm
- Disparities in the Population at Risk of Severe Illness From COVID-19 by Race/Ethnicity and Income
- Mandatory Social Distancing Associated With Increased Doubling Time: An Example Using Hyperlocal Data
Progress in Disaster Science: COVID-19 Special Collection
Keeping wider disciplinary involvement in mind, the journal Progress in Disaster Science plans to publish special issues as a major learning from the evolving nature of the pandemic. Papers on the following topics related to COVID-19 response are encouraged: public health response, governance and policy analysis, emerging technologies, roles of civil societies and other stakeholders, citizen participation, collateral hazards, business continuity, recovery planning, economic/fiscal implications. Read the special collection
Journal of Aerosol Science: Special section on "Virus Aerosol Science, Sampling, and Control"
The editor, Prof. Chris Hogan, writes: "The Journal of Aerosol Science has long been a resource on understanding viruses in aerosols, methods to sample airborne viruses, and to control and inactivate airborne viruses. In this collection, we highlight numerous studies over the past decade focusing on virus aerosol science. In addition, we invite authors to contribute this virtual collection by submitting to this journal, selecting the option: "SARS-CoV-2 & Virus Aerosols." Read the special section
COVID-19 podcasts and webinars by CIDRAP
Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here
More public health resources
- Interactive map shows global spread of COVID-19 (Johns Hopkins CSSE)
- Information and updates (CDC)
- CDC vaccine guidance
- Travel health notices (CDC)
- Novel coronavirus advice for the public (WHO)
- Building a Resilient Recovery (OECD)
- Disaster Epidemiology and Surveillance, Chapter 27, Jekel's Epidemiology, Biostatistics, Preventive Medicine, and Public Health, 5th Edition (Elsevier, 2020)
Official guidance from various countries:
عدوى فيروس كورونا المستجد (patient education in Arabic)
Elsevier's Patient Access Program for research
With our Patient Access Program, patients and their caregivers can receive medical or healthcare related research papers by emailing firstname.lastname@example.org. This email is constantly monitored by our support teams, who aim to provide individual articles at no cost to patients and caregivers within 24 hours. Requesters simply need to include the article title and authors, date published, and/or the DOI or URL if available so we can locate the article as quickly as possible. Learn more
COVID-19 podcasts and webinars
Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here
Since January 2020, Elsevier has created an online resource center with free information in English and Mandarin on the novel coronavirus (COVID-19).
This Novel Coronavirus Information Center is hosted on Elsevier Connect, the company’s public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource center — including this research content — immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource center remains active.